<DOC>
	<DOCNO>NCT00192517</DOCNO>
	<brief_summary>The primary objective study compare effect disease activity , absence systemic psoriasis therapy , 4 mg/kg MEDI-522 versus placebo administer weekly SC injection 12 week .</brief_summary>
	<brief_title>Study MEDI-522 Administered Subcutaneous Injection Adults With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Plaque psoriasis involve least 10 % body surface area ( Appendix A ) PASI score great 12 Age 18 65 year time first dose study drug Both males female eligible . However , sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 30 day prior first dose study drug must agree continue use precaution 60 day final dose study drug Prior randomization ( must within 21 day first administration study drug ) , follow : WBC le equal 3,800/mm3 ; hematocrit 32 % , platelet count less equal 140,000/mm3 ; AST , ALT , BUN , creatinine &lt; 1.5 x ULN ; stool negative occult blood Currently receive therapy psoriasis except emollient Written inform consent obtain patient Ability complete followup period 167 day require protocol Pustular , guttate , erythrodermic psoriasis predominant disease type Evidence active hepatitis A , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection , positive HBsAg positive antihepatitis C antibody Pregnancy ( must negative serum pregnancy test within 21 day prior first dose study drug , urine pregnancy test must negative Study Day 0 study entry ) History cancer ( except excision basal cell carcinoma ) Evidence significant active infection , fever less great 38.0°C ( 100.5°F ) , chronic systemic infection Known suspect infection human immunodeficiency virus ( HIV ) evidence clinically significant immune deficiency Diagnosis psoriatic arthritis rheumatoid arthritis require active treatment History hematuria due chronic cystitis , recurrent kidney stone , nephritis , history CVA , poorly control hypertension , angina , stable abdominal aneurysm , recent superficial phlebitis , recent myocardial infarction ( within past 1 year without definitive corrective surgery coronary bypass graft angioplasty ) Receipt systemic therapy psoriasis immunosuppressive medication past 4 week , include systemic retinoids , systemic steroid ( oral , IM , IV ) , cyclosporine A , methotrexate , azathioprine , antiTNF agent , antiTcell agent , phototherapy ( PUVA , UVB , tan bed use ) , coal tar treatment ( Goeckerman modify Goeckerman regimen ) , tacrolimus , mycophenolate Use topical therapy psoriasis past 2 week , steroid contain cream , Vitamin D analog cream coal tar shampoos Receipt investigational drug therapy within 4 week first dose study drug protocol ( use license agent indication list package insert permit ) Current plan participation research protocol investigational agent therapy may administer History allergic disease reaction likely exacerbate component MEDI522 Nursing mother Evidence acute illness Clinical manifestation significant end organ dysfunction failure may compromise safety patient study History gastrointestinal bleeding ( i.e. , stool positive occult blood overt bleed ) within previous 6 month Known bleed disorder significant risk clinically important abnormal bleeding due anticoagulant therapy warfarin heparin Insulindependent diabetes mellitus recentonset unstable Elective surgery plan study period Study Day 167</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>